Antagonist of the Glucagon-like Peptide 2 (GLP-2) Receptor
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- SMA blood flow
研究概览
简要总结
This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.
详细描述
Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-70 years
- •BMI 19-28 kg/m2
排除标准
- •Chronic illness that affects the cardiovascular system or gastrointestinal tract
- •Treatment with medicine or supplements that cannot be paused for 12 hours
- •Intake of above 14 alcoholic drinks per week or substance abuse
- •Liver enzymes (ALAT) above 2 times normal values
- •Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
- •Low blood percentage (hemoglobin below reference value)
- •Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.
研究组 & 干预措施
Saline injection + Saline infusion (SAL-SAL)
Saline subcutaneous injection, Intravenous saline infusion (NaCl (9 mg/ml))
干预措施: Saline infusion (Other)
Saline injection + Saline infusion (SAL-SAL)
Saline subcutaneous injection, Intravenous saline infusion (NaCl (9 mg/ml))
干预措施: Saline injection (Other)
GLP-2 agonist injection + Saline infusion (AGO-SAL)
Subcutaneous injection of GLP-2 (1-33) agonist, Intravenous infusion of saline (NaCl (9 mg/ml))
干预措施: Saline infusion (Other)
GLP-2 agonist injection + Saline infusion (AGO-SAL)
Subcutaneous injection of GLP-2 (1-33) agonist, Intravenous infusion of saline (NaCl (9 mg/ml))
干预措施: Agonist injection (Other)
GLP-2 agonist injection + GLP-2 1 nmol antagonist infusion (AGO-1ANT)
Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 1 nmol/kg/min GLP-2 (3-33) antagonist
干预措施: 1nmol antagonist infusion (Other)
GLP-2 agonist injection + GLP-2 1 nmol antagonist infusion (AGO-1ANT)
Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 1 nmol/kg/min GLP-2 (3-33) antagonist
干预措施: Agonist injection (Other)
GLP-2 agonist injection + GLP-2 4 nmol antagonist infusion (AGO-4ANT)
Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 4 nmol/kg/min GLP-2 (3-33) antagonist
干预措施: 4 nmol antagonist infusion (Other)
GLP-2 agonist injection + GLP-2 4 nmol antagonist infusion (AGO-4ANT)
Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 4 nmol/kg/min GLP-2 (3-33) antagonist
干预措施: Agonist injection (Other)
结局指标
主要结局
SMA blood flow
时间窗: 85 minutes
Blood flow in the superior mesenteric artery
次要结局
- PVblood flow(85 minutes)